The present invention features a compound of formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, where R.sub.1, R.sub.2, R.sub.3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

The present invention features a compound of formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, where R.sub.1, R.sub.2, R.sub.3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3 OH kinase family (hereinafter PI3 kinases), suitably, PI3K, PI3K, PI3K, and/or PI3K. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K selective benzimidazoles compounds for treating cancer.

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3 OH kinase family (hereinafter PI3 kinases), suitably, PI3K, PI3K, PI3K, and/or PI3K. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K selective benzimidazoles compounds for treating cancer.

The present disclosure relates in part to sterically hindered N-aliphatic N-heterocyclic carbene (NHC) ligands, which are readily synthetically available from inexpensive starting materials. The present disclosure further relates to NHC catalyst complexes comprising transition metals such as Cu, Ag, Au, and Pd. Furthermore, the present disclosure provides methods for using the catalysts described herein in a number of organic transformations, including alkyne hydroboration and hydration, in addition to CO, CC, and CN coupling reactions.

A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3 OH kinase family (hereinafter PI3 kinases), suitably, PI3K, PI3K, PI3K, and/or PI3K. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K selective benzimidazoles compounds for treating cancer.

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3 OH kinase family (hereinafter PI3 kinases), suitably, PI3K, PI3K, PI3K, and/or PI3K. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K selective benzimidazoles compounds for treating cancer.

Provided herein are compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.